PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12016742::ACT015731

GI

Evidence text

Paper-level observation

StCl‐GI_GII treatment increased the percentage of MHCI‐expressing LECs (P < 0.0001) while decreasing the percentage of MHCII‐ (P = 0.0236) and PD‐L1‐expressing LECs (P < 0.0001) (Figure S16a–d,h) in tumor‐draining lymph nodes when compared to the same tissues in untreated mice.
textConfidence: medium

Assay observation

Activity
Immunomodulatory
Subtype
Antibacterial
Measure
percent_inhibition
Comparator
=
Raw observation
P = 0.0236 vs untreated
Normalized measurement
=0.0236
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
Mus musculus
Assay method
Not reported by source
Sequence
EGSRNQDWL
Standardization
ready simple

Source publication

Off‐The‐Shelf Multivalent Nanoconjugate Cancer Vaccine Rescues Host Immune Response against Melanoma

Advanced Materials · 2025

DOI 10.1002/adma.202417348 PMC12016742
Parent mention

Related peptide identities

PEPDIA-PLP-000563

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.